About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Multiple Sclerosis Drug: FDA Approves Ocrelizumab For Treatment

by Madhumathi Palaniappan on March 31, 2017 at 2:42 PM
Font : A-A+

Multiple Sclerosis Drug: FDA Approves Ocrelizumab For Treatment

The United States Food and Drug Administration (FDA) has recently approved ocrelizumab drug for the treatment of a rare form of multiple sclerosis.

Multiple sclerosis is a neurological disorder, which affects thousands of people and commonly women in the United States.

Advertisement


Billy Dunn, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said, "Multiple sclerosis can have a profound impact on a person's life."

"This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS."
Advertisement

According to the Centers for Disease Control and Prevention, around 15% of patients have primary progressive multiple sclerosis.

Ocrelizumab Drug
Ocrelizumab drug is a monoclonal antibody which comes under the name Ocrevus. The intravenous infusion is administered every six months. The drug mainly acts by stamping out the class of the immune cells known as B cells.

Clinical Trial Findings
  • The findings of the drug showed that the progression of primary progressive multiple sclerosis was slowed down by 24% when compared with placebo.
  • The relapse rates of multiple sclerosis showed 46% drop in annual relapse rates when compared to other drugs like interferon.
  • Around 48% of the patients in the relapsing- remitting multiple sclerosis had no relapses and had no worsening symptoms of neurological symptoms.
Side Effects
  • Itchy skin
  • Rashes or redness of the skin
  • Low blood pressure
  • Fever
  • Tiredness
  • Dizziness
  • Headache
  • Breathing difficulties
  • Upper Respiratory tract infections
Multiple Sclerosis
Multiple sclerosis is a chronic, autoimmune disease of the central nervous system found to disrupt the communication between the brain and the other parts of the body.

Symptoms of multiple sclerosis usually occur between the age of 20 and 40 years.

There is no specific treatment for primary progressive multiple sclerosis and the drug is found to reduce relapse rates and the worsening of disability when compared to other drugs.

Further, the FDA has granted approval for the drug to Genentech. The drug will be made available at a price of $65000 per year.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chemotherapy Chemotherapy Drugs Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

Most Popular on Medindia

Noscaphene (Noscapine) Drug Interaction Checker Color Blindness Calculator Blood Pressure Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Sinopril (2mg) (Lacidipine) Find a Hospital Selfie Addiction Calculator Calculate Ideal Weight for Infants Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Multiple Sclerosis Drug: FDA Approves Ocrelizumab For Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests